[ET Net News Agency, 1 September 2021] Sino Biopharmaceutical Limited (01177) said
"Sofosbuvir Tablets" (brand name: Suoweidi), a new antiviral drug developed by the group,
has obtained drug registration certificate granted by the National Medical Products
Administration of the PRC, being the second generic drug of its kind that has obtained
approval for drug registration in the PRC, and is deemed to have passed the Consistency of
Quality and Efficacy Evaluation for Generic Drugs.
Sofosbuvir is used for the treatment of Chronic Hepatitis C Virus (HCV) infection as it
has the characteristic of pan-genotypic efficacy, high clinical recovery rate, easy
medication, no significant side effects, low incidence of virus resistance, and high
safety and effectiveness on patients with severe liver disease. The introduction of
Sofosbuvir makes Hepatitis C become a clinical completely curable disease. Currently,
various new domestic and international guidelines have recommended Sofosbuvir as the
firstline treatment for Hepatitis C. (RC)
|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01177 SINO BIOPHARM
Nominal 
2.770 +0.030 (+1.095%) Others
01/09/2021 17:56
Sino Biopharm (01177) gets drug registration certificate
| Remark: | Real time quote last updated: 26/04/2024 18:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service |